Chronic obstructive pulmonary disease: the disease and its burden to society.

Chronic obstructive pulmonary disease (COPD) is a multicomponent disease with inflammation at its core, and a major cause of morbidity and mortality. It represents a substantial economic and social burden throughout the world. Currently, COPD is the fifth leading cause of death worldwide, and despite advances in management, mortality is expected to increase in the coming decades, in marked contrast to other chronic diseases, such as heart disease and stroke, where there have been considerable decreases in mortality. On a patient level, the burden of COPD to patients and their families and carers is high, both in terms of health-related quality of life and health status. Health care providers and patients often underestimate the substantial morbidity associated with COPD; the condition is also frequently underdiagnosed and undertreated, which further compromises morbidity. Reducing the burden of COPD requires better evaluation and diagnosis, as well as improved management of chronic symptoms. As exacerbations and hospitalizations represent an important driver of the cost and morbidity of COPD, high priority should be given to interventions aimed at delaying the progression of disease, preventing exacerbations, and reducing the risk of comorbidities to alleviate the clinical and economic burden of disease.

[1]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[2]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[3]  A. Reunanen,et al.  Airway obstruction in relation to symptoms in chronic respiratory disease--a nationally representative population study. , 2000, Respiratory medicine.

[4]  J. Wedzicha,et al.  Causes of death in patients with COPD and chronic respiratory failure. , 1997, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[5]  B. Lindgren,et al.  The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. , 2000, Respiratory medicine.

[6]  J. Plummer,et al.  The prevalence of chronic bronchitis, chronic airway obstruction, and respiratory symptoms in a Colorado city. , 1971, The American review of respiratory disease.

[7]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[8]  J C Jager,et al.  Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. , 1999, Respiratory medicine.

[9]  A. Gulsvik,et al.  Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. , 1991, Thorax.

[10]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[11]  A. Jemal,et al.  Trends in the leading causes of death in the United States, 1970-2002. , 2005, JAMA.

[12]  N. Pride,et al.  Recent trends in physician diagnosed COPD in women and men in the UK , 2000, Thorax.

[13]  A. Gulsvik.  Prevalence and manifestations of obstructive lung disease in the city of Oslo. , 1979, Scandinavian journal of respiratory diseases.

[14]  A. Hansell,et al.  What do chronic obstructive pulmonary disease patients die from? Amultiple cause coding analysis , 2003, European Respiratory Journal.

[15]  X. Busquets,et al.  Systemic effects of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[16]  J. Tu,et al.  Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[17]  S. Sullivan,et al.  The costs of treating COPD in the United States. , 2001, Chest.

[18]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[19]  E. Wouters,et al.  Weight Loss Is a Reversible Factor in the Prognosis of Chronic Obstructive Pulmonary Disease , 1998 .

[20]  G. Viegi,et al.  Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. , 2005, Respiratory medicine.

[21]  D. Roblin,et al.  Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. , 2006, Respiratory medicine.

[22]  R. Pauwels,et al.  COPD exacerbations: the importance of a standard definition. , 2004, Respiratory medicine.

[23]  J. Izquierdo,et al.  The burden of COPD in Spain: results from the Confronting COPD survey. , 2003, Respiratory medicine.

[24]  L. Wilson,et al.  Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. , 2000, Respiratory medicine.

[25]  E. Rönmark,et al.  The costs of exacerbations in chronic obstructive pulmonary disease (COPD). , 2002, Respiratory medicine.

[26]  Ramon Gisbert,et al.  Costs of chronic bronchitis and COPD: a 1-year follow-up study. , 2003, Chest.

[27]  M. Malesker,et al.  Pharmacoeconomic evaluation of COPD. , 2000, Chest.

[28]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[29]  M. Cazzola,et al.  Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. , 2005, Respiratory medicine.

[30]  G. Viegi,et al.  Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. , 2000, Chest.

[31]  A. Pont,et al.  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study , 2004, Thorax.

[32]  T L Petty,et al.  Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. , 2000, Archives of internal medicine.

[33]  C. Jenkins,et al.  The TORCH (TOwards a Revolution in COPD Health) survival study protocol , 2004, European Respiratory Journal.

[34]  D. Mannino,et al.  Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. , 1997, American journal of respiratory and critical care medicine.

[35]  J. Dickinson,et al.  Screening older patients for obstructive airways disease in a semi-rural practice , 1999, Thorax.

[36]  M. Miravitlles,et al.  Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. , 2000, Chest.

[37]  Judith K Jones,et al.  Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. , 2006, Annals of epidemiology.

[38]  S. Borg,et al.  Costs of COPD in Sweden according to disease severity. , 2002, Chest.

[39]  John R Hurst,et al.  Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[40]  L Goldman,et al.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.

[41]  P. Laippala,et al.  Prevalence of chronic obstructive pulmonary disease in elderly Finns. , 1994, Respiratory medicine.

[42]  R. Phillips,et al.  A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. , 1998, The American journal of medicine.

[43]  A. Iqbal,et al.  Interpreting COPD prevalence estimates: what is the true burden of disease? , 2003, Chest.

[44]  M. Miravitlles,et al.  [Attitudes toward the diagnosis of chronic obstructive pulmonary disease in primary care]. , 2006, Archivos de bronconeumologia.

[45]  Rafael Gabriel,et al.  Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers. , 2005, Respiratory medicine.

[46]  John Connett,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[47]  E. Wouters.  Economic analysis of the Confronting COPD survey: an overview of results. , 2003, Respiratory medicine.

[48]  M. Decramer,et al.  Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey , 2002, European Respiratory Journal.

[49]  Alan D. Lopez,et al.  The global burden of disease, 1990–2020 , 1998, Nature Medicine.